Mereo BioPharma Group plc (MREO)
$0.32+0.00%Close
BUYCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $51M
- Beta
- 0.30
- P/E (TTM)
- -1.76
- Short % float
- 1.68%
- Days to cover
- 1.3
- SI change
- -12.9%
- 1W
- -8.57%
- 1M
- +14.29%
- vs SPY 1W
- -8.43%
- vs SPY 1M
- +11.78%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 11
- VALUE
- 7
- GROWTH
- 47
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-44.9%
REV YoY-
ROE-74.8%
EPS YoY-
ROA-80.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.76
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.79
P/FCF-
EV/EBITDA-0.67
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E3.59
ALTMAN Z-
CURR RATIO5.88
ND/EBITDA-
BETA0.30
Company news
FAQ
- What is LOPJLB’s current signal on MREO?
- LOPJLB’s latest quantitative signal on Mereo BioPharma Group plc (MREO) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is MREO in?
- Mereo BioPharma Group plc (MREO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Mereo BioPharma Group plc (MREO) do?
- Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently unde…